Value of protein-bound radioactive iodine measurements in the management of differentiated thyroid cancer treated with (131)I

Br J Radiol. 2001 May;74(881):429-33. doi: 10.1259/bjr.74.881.740429.

Abstract

Measurement of the protein-bound radioactive iodine level (PBI(131)) in the plasma of patients following (131)I-iodide administration for thyroid cancer has been re-examined in a retrospective study of 171 patient episodes. It is shown that whereas the previously used threshold value for the measurement at 6 days does not correlate well with the 3-day whole body scan, there is good agreement between the scan and the temporal changes in PBI(131) from 1-6 days: an increasing PBI(131) correlates with a positive scan, and a decreasing PBI(131) with a negative scan. The area under the curve (AUC) for the PBI(131)-time curve is related to the absorbed dose for the tumour. For a small group of 11 patients, dosimetry estimates were made from serial scans, quantified with phantoms; these absorbed doses correlated with the AUC and the 6-day PBI(131). Therefore, it is suggested that these parameters may be useful in predicting absorbed radiation dose in these patients.

MeSH terms

  • Absorption
  • Anion Exchange Resins
  • Area Under Curve
  • Gamma Cameras
  • Humans
  • Iodine Radioisotopes / blood*
  • Iodine Radioisotopes / pharmacokinetics
  • Iodine Radioisotopes / therapeutic use
  • Phantoms, Imaging
  • Protein Binding
  • Radiometry
  • Retrospective Studies
  • Thyroid Neoplasms / blood
  • Thyroid Neoplasms / diagnostic imaging
  • Thyroid Neoplasms / radiotherapy*
  • Thyroxine-Binding Proteins / metabolism
  • Tomography, Emission-Computed

Substances

  • Anion Exchange Resins
  • Iodine Radioisotopes
  • Thyroxine-Binding Proteins